FDA Authorizes Changes to Monkeypox Vaccine

Yesterday, the FDA issued an Emergency Use Authorization that allows health-care providers to change how the Jynneos Monkeypox vaccine is administered. With the change, the vaccine can now be given to high-risk adults intradermally, or between layers of skin, versus subcutaneously, or under the skin, which will allow providers to get five doses out of a standard one-dose vial. The new order also allows subcutaneous vaccination in people under the age of 18 who are at high risk. The move will increase the number of vaccine doses in the national stockpile from 441,000 to over 2.2 million. The CDC has estimated that at least 1.5 million people in the United States are currently eligible for the two-dose vaccine and reports nearly 9,500 probable or confirmed cases of the virus in 49 states, Puerto Rico and the District of Columbia.